A Trial of SHR0302Base in Patients With Vitiligo

Inclusion Criteria:

1. Clinically diagnosis of non-segmental vitiligo.

2. The disease has been stable for more than 3 months (90 days) (stable disease isdefined as no expansion of the original lesion and no new lesions).

3. Subjects and their partners do not plan to have children, do not donate sperm/eggs,and voluntarily use highly effective contraception during the study period until 6months (female subjects) or 3 months (male subjects) after dosing. Female subjectsmust have a negative serum pregnancy test and be non-lactating.

Exclusion Criteria:

1. Subjects diagnosed with segmental, mixed or undifferentiated vitiligo; Or previouslydiagnosed with other skin pigmentation disorders (except nevus halos).

2. Conditions at baseline that would interfere with evaluation of vitiligo.

3. Participants who have used skin bleaching treatments for past treatment of vitiligoor other pigmented areas.

4. Use of protocol-defined treatments within the indicated washout period beforebaseline.